This thorough review investigates post-treatment hemoglobin levels of cancer in neck and head survivors one year following treatment completion. Pretreatment hemoglobin values can be utilised to predict prognosis in patients receiving concomitant chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Anemia, a frequent laboratory abnormality in oncology, is linked to a reduced cellular oxygen supply. This, in turn, affects tumour cell radiosensitivity and reduces the efficiency of treatment therapies. Understanding the pretreatment haemoglobin readings is therefore critical in predicting results for individuals undertaking this specific therapy regimen. Patients with HNC (head and neck cancers) are increasingly surviving in greater numbers, accounting for up to 3 percent of all cancer survivors. This is most likely owing to an increase in HPV-related oropharyngeal cancers affecting younger people with a better prognosis, as well as improved outcomes in other HNCs during the previous two decades. Previously, most research focused on improving risk classification, treatment, and illness outcomes. There has been a growing interest in the topic of survivorship care during the last decade. Despite the joint efforts of a multidisciplinary team in controlling cancer and treatment-related side effects, as well as enhancing survivors' overall quality of life (QOL), it has been observed that up to 60-65% of patients have at least one of these conditions. Poor nutritional status is linked to tumour development and survival in individuals with HNSCC (head and neck squamous cell carcinoma). Nutritional and hematological parameters' predictive significance in HNSCC patients who received final treatment. The goal of this research was to investigate the link between financial toxicity and survival in patients with HNC (head and neck cancer). The focus of this study was to see if nutritional status indicators predict locoregional failure after intensity-modulated radiation treatment (IMRT) with concurrent chemoradiotherapy (CCRT) for SCCHN(squamous cell carcinoma of the head and neck).